Nurix Therapeutics Statistics
Share Statistics
Nurix Therapeutics has 76.24M
shares outstanding. The number of shares has increased by 17.92%
in one year.
| Shares Outstanding | 76.24M |
| Shares Change (YoY) | 17.92% |
| Shares Change (QoQ) | 7.13% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 14,236 |
| FTD / Avg. Volume | 1.44% |
Short Selling Information
The latest short interest is 13.69M, so 17.96% of the outstanding
shares have been sold short.
| Short Interest | 13.69M |
| Short % of Shares Out | 17.96% |
| Short % of Float | 21.1% |
| Short Ratio (days to cover) | 12.77 |
Valuation Ratios
The PE ratio is -7.67 and the forward
PE ratio is -2.81.
Nurix Therapeutics's PEG ratio is
-0.88.
| PE Ratio | -7.67 |
| Forward PE | -2.81 |
| PS Ratio | 27.21 |
| Forward PS | 1.6 |
| PB Ratio | 2.82 |
| P/FCF Ratio | -8.16 |
| PEG Ratio | -0.88 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Nurix Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.46,
with a Debt / Equity ratio of 0.05.
| Current Ratio | 6.46 |
| Quick Ratio | 6.46 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $190,730.77 |
| Profits Per Employee | $-676,814.69 |
| Employee Count | 286 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 270K |
| Effective Tax Rate | -0.14% |
Stock Price Statistics
The stock price has increased by -27.12% in the
last 52 weeks. The beta is 2.24, so Nurix Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.24 |
| 52-Week Price Change | -27.12% |
| 50-Day Moving Average | 11.68 |
| 200-Day Moving Average | 19.3 |
| Relative Strength Index (RSI) | 43.39 |
| Average Volume (20 Days) | 985,706 |
Income Statement
In the last 12 months, Nurix Therapeutics had revenue of 54.55M
and earned -193.57M
in profits. Earnings per share was -2.88.
| Revenue | 54.55M |
| Gross Profit | 38.12M |
| Operating Income | -213.03M |
| Net Income | -193.57M |
| EBITDA | -196.6M |
| EBIT | -213.03M |
| Earnings Per Share (EPS) | -2.88 |
Full Income StatementBalance Sheet
The company has 110M in cash and 28.3M in
debt, giving a net cash position of 81.69M.
| Cash & Cash Equivalents | 110M |
| Total Debt | 28.3M |
| Net Cash | 81.69M |
| Retained Earnings | -738.77M |
| Total Assets | 615.04M |
| Working Capital | 473.71M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -172.58M
and capital expenditures -9.27M, giving a free cash flow of -181.86M.
| Operating Cash Flow | -172.58M |
| Capital Expenditures | -9.27M |
| Free Cash Flow | -181.86M |
| FCF Per Share | -2.71 |
Full Cash Flow StatementMargins
Gross margin is 69.88%, with operating and profit margins of -390.52% and -354.85%.
| Gross Margin | 69.88% |
| Operating Margin | -390.52% |
| Pretax Margin | -354.36% |
| Profit Margin | -354.85% |
| EBITDA Margin | -360.41% |
| EBIT Margin | -390.52% |
| FCF Margin | -333.38% |
